Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Why Coherus Biosciences Popped Today
03:41pm, Monday, 22'nd Jan 2024
Coherus announced a $170 million deal to divest Cimerli to Sandoz Group. The company is paying down debt and refocusing on its core oncology business.
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
08:38am, Monday, 22'nd Jan 2024
Coherus BioSciences (NASDAQ: CHRS ) stock is taking off on Monday after the biopharmaceutical company announced a $170 million divestment. Coherus BioSciences is selling its CIMERLI ophthalmology fr
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
09:00am, Wednesday, 03'rd Jan 2024
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Mo
Why Coherus BioSciences Stock Jumped Today
03:45pm, Thursday, 28'th Dec 2023
After months of delays following an FDA review of its Udenyca OnBody biologics license application, Coherus has finally received FDA approval for the product. Coherus is planning commercial availabili
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
12:47pm, Thursday, 28'th Dec 2023
The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.
Coherus BioSciences shares take off on FDA approval of drug delivery device
11:01am, Wednesday, 27'th Dec 2023
Coherus BioSciences (NASDAQ:CHRS) shares gained more than 20% in early trade on Wednesday after it revealed that the United States Food and Drug Administration (FDA) has approved UDENYCA ONBODY, the c
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
06:56am, Wednesday, 27'th Dec 2023
The S&P 500 index SPX has three days left this year to try for a fresh record high, which in theory, shouldn't be so hard with a Santa Rally all but teed up.
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
09:45am, Sunday, 24'th Dec 2023
Small-cap stocks took the brunt of the 2022 bear market and many names have yet to recover. Agenus and Coherus BioSciences are prime examples.
Why Coherus BioSciences Was Plummeting This Week
03:15pm, Friday, 10'th Nov 2023
Few investors were impressed by the biotech's third-quarter performance. This included several analysts, one of whom went as far as to downgrade his recommendation.
Coherus: The Surface Acquisition Is A Distraction
05:37pm, Tuesday, 07'th Nov 2023
Coherus BioSciences recently received US approval for toripalimab, but the stock is down 30% since July. The company's acquisition of Surface Oncology adds to its risk profile and raises concerns. CHR
Why Coherus Biosciences Stock Dropped Today
03:37pm, Tuesday, 07'th Nov 2023
Coherus delivered weaker-than-expected revenue and earnings for the third quarter. It also lowered its revenue outlook for the year, blaming delays in its planned commercial launches for Udenyca OnBod
Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript
12:03am, Tuesday, 07'th Nov 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - President, CEO and
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
03:32pm, Monday, 06'th Nov 2023
Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.
Coherus BioSciences to Participate at Upcoming November Investor Conferences
08:00pm, Thursday, 02'nd Nov 2023
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor confer
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
06:00pm, Monday, 30'th Oct 2023
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after mar
